BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17051349)

  • 1. Risks of cancer due to a single BRCA1 mutation in an extended Utah kindred.
    Vogl FD; Badzioch MD; Steele L; Neuhausen SL; Goldgar DE
    Fam Cancer; 2007; 6(1):63-71. PubMed ID: 17051349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer.
    Heimdal K; Maehle L; Apold J; Pedersen JC; Møller P
    Eur J Cancer; 2003 Oct; 39(15):2205-13. PubMed ID: 14522380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.
    Einbeigi Z; Bergman A; Meis-Kindblom JM; Flodin A; Bjursell C; Martinsson T; Kindblom LG; Wahlström J; Wallgren A; Nordling M; Karlsson P
    Fam Cancer; 2007; 6(1):35-41. PubMed ID: 16944270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations.
    Marroni F; Aretini P; D'Andrea E; Caligo MA; Cortesi L; Viel A; Ricevuto E; Montagna M; Cipollini G; Federico M; Santarosa M; Marchetti P; Bailey-Wilson JE; Bevilacqua G; Parmigiani G; Presciuttini S
    Eur J Hum Genet; 2004 Nov; 12(11):899-906. PubMed ID: 15340362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
    van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
    Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
    Chen S; Iversen ES; Friebel T; Finkelstein D; Weber BL; Eisen A; Peterson LE; Schildkraut JM; Isaacs C; Peshkin BN; Corio C; Leondaridis L; Tomlinson G; Dutson D; Kerber R; Amos CI; Strong LC; Berry DA; Euhus DM; Parmigiani G
    J Clin Oncol; 2006 Feb; 24(6):863-71. PubMed ID: 16484695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies.
    Antoniou AC; Pharoah PD; Narod S; Risch HA; Eyfjord JE; Hopper JL; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tulinius H; Thorlacius S; Eerola H; Nevanlinna H; Syrjäkoski K; Kallioniemi OP; Thompson D; Evans C; Peto J; Lalloo F; Evans DG; Easton DF
    J Med Genet; 2005 Jul; 42(7):602-3. PubMed ID: 15994883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
    Bogdanova NV; Antonenkova NN; Rogov YI; Karstens JH; Hillemanns P; Dörk T
    Clin Genet; 2010 Oct; 78(4):364-72. PubMed ID: 20569256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study.
    Antoniou AC; Pharoah PD; McMullan G; Day NE; Ponder BA; Easton D
    Genet Epidemiol; 2001 Jul; 21(1):1-18. PubMed ID: 11443730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of BRCA1 and BRCA2 penetrance.
    Chen S; Parmigiani G
    J Clin Oncol; 2007 Apr; 25(11):1329-33. PubMed ID: 17416853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic analysis of eight breast-ovarian cancer families with suspected BRCA1 mutations.
    Couch FJ; Garber J; Kiousis S; Calzone K; Hauser ER; Merajver SD; Frank TS; Boehnke M; Chamberlain JS; Collins FS
    J Natl Cancer Inst Monogr; 1995; (17):9-14. PubMed ID: 8573462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk models for familial ovarian and breast cancer.
    Antoniou AC; Gayther SA; Stratton JF; Ponder BA; Easton DF
    Genet Epidemiol; 2000 Feb; 18(2):173-90. PubMed ID: 10642429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A large kindred with 17q-linked breast and ovarian cancer: genetic, phenotypic, and genealogical analysis.
    Goldgar DE; Fields P; Lewis CM; Tran TD; Cannon-Albright LA; Ward JH; Swensen J; Skolnick MH
    J Natl Cancer Inst; 1994 Feb; 86(3):200-9. PubMed ID: 8283492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
    Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
    J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
    Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubiñski J; Scott RJ; Hamann U
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):270-5. PubMed ID: 17301259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.
    Merajver SD; Frank TS; Xu J; Pham TM; Calzone KA; Bennett-Baker P; Chamberlain J; Boyd J; Garber JE; Collins FS
    Clin Cancer Res; 1995 May; 1(5):539-44. PubMed ID: 9816013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
    King MC; Marks JH; Mandell JB;
    Science; 2003 Oct; 302(5645):643-6. PubMed ID: 14576434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.